Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Restructuring Costs (2025)

Zentalis Pharmaceuticals has reported Restructuring Costs over the past 1 years, most recently at -$4000.0 for Q4 2025.

  • Quarterly results put Restructuring Costs at -$4000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $7.8 million (changed N/A YoY), and the annual figure for FY2025 was $7.8 million, changed.
  • Restructuring Costs for Q4 2025 was -$4000.0 at Zentalis Pharmaceuticals, down from $7.8 million in the prior quarter.
  • Over the last five years, Restructuring Costs for ZNTL hit a ceiling of $7.8 million in Q1 2025 and a floor of -$4000.0 in Q4 2025.